Enabling breakthrough antibody-based therapies
Our unique suite of technologies enables us to create a series of highly innovative targeted biotherapeutics. We are open to strategic partnership that support our core strategy and increase the value of our growing BiTAC and ADC drug pipeline.
Product partnerships
VERAXA has established a proprietary pipeline of highly innovative drug candidates applying its antibody, antibody-drug conjugate and novel bispecific-targeting capabilities.
Our most advanced project has delivered promising phase-1 clinical trial results and addresses FLT-3, a promising target molecule, which is overexpressed in the majority of AML cancer cells.
R&D alliances
VERAXA is open to collaborate with partners on de novo projects bringing together our innovative suite of technologies with novel target combinations in oncology and potentially other indications.
If you want to learn more about ways to partner with VERAXA, reach out via partnering@veraxa.com or meet us at one of the upcoming conferences.
If you are interested in partnering with us
We are your partner from target to antibody to ADC. Our unique antibody screening platform and proprietary ADC technology enable us to help you create the best targeted biotherapeutics for your application.
With partnership models tailored to your needs, we can join you at any step of your development journey, whether you are starting out with a target or are looking for a bioconjugation partner.